A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Public ClinicalTrials.gov record NCT03035279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006 dose expansion), and Part C (SC-006 and ABBV-181 combination escalation and expansion). Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended Part B dose and schedule. Part B (dose expansion) will enroll additional participants who will be treated with a study drug dose at or below the MTD determined in Part A. Part C is dose escalation of SC-006 and fixed dose of ABBV-181 in combination. Recommended dose cohort of SC-006 with ABBV-181 will be expanded.
Study identification
- NCT ID
- NCT03035279
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 29 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2017
- Primary completion
- Mar 27, 2019
- Completion
- Mar 27, 2019
- Last update posted
- Feb 19, 2020
2017 – 2019
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group /ID# 201182 | Fayetteville | Arkansas | 72703-4005 | — |
| University of California, Los Angeles /ID# 160882 | Los Angeles | California | 90095 | — |
| University of Michigan Hospitals /ID# 167101 | Ann Arbor | Michigan | 48109-5008 | — |
| Mayo Clinic - Rochester /ID# 160884 | Rochester | Minnesota | 55905-0001 | — |
| Washington University-School of Medicine /ID# 160883 | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center /ID# 160881 | New York | New York | 10065-6007 | — |
| Carolina BioOncology Institute /ID# 202712 | Huntersville | North Carolina | 28078 | — |
| Oklahoma University /ID# 202713 | Oklahoma City | Oklahoma | 73104 | — |
| Tennessee Oncology-Nashville Centennial /ID# 160880 | Nashville | Tennessee | 37203-1632 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03035279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2020 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03035279 live on ClinicalTrials.gov.